The GLP-1 Affordability Gap: What the Numbers Actually Show

A Medication Problem That's Really a Pricing Problem

Here's a strange fact about the most talked-about drug class in America: the medicine works, the demand is enormous, and almost nobody who qualifies is on it. Estimates suggest fewer than one in ten eligible US adults takes a GLP-1.

The gap isn't skepticism. Search interest in semaglutide grew more than thirtyfold between 2020 and 2024. The gap is a price wall — and unlike most health-policy problems, this one is unusually well documented.

Three Data Points That Define the Gap

People say cost hurts. KFF's polling of adults who have taken GLP-1s found roughly half describing the medications as difficult to afford — a striking figure for people who managed to start at all.

Cost predicts who persists. The Rodriguez JAMA Network Open cohort (125,474 patients) found household income above $80,000 associated with a 28% lower discontinuation rate among diabetic patients. Read that carefully: the same medication, the same efficacy, different wallets — different outcomes. The authors' own conclusion warned that access and adherence inequities "have the potential to exacerbate disparities in obesity."

Insurance hasn't closed it. Many commercial plans still exclude weight-management medications outright; prior authorization gauntlets and denials filter out much of the rest. The uninsured — disproportionately Hispanic adults, who also face elevated obesity and diabetes rates — never reach the starting line. (It's part of why we built the full platform in Spanish.)

The 2026 Price Map

Our pricing index tracks the all-in numbers across 90+ providers — including membership fees and refill jumps the advertised prices omit. The pattern it documents: advertised prices and paid prices are frequently different numbers, and the difference lands hardest on exactly the patients the affordability data already flags.

Why This Framing Matters

If cost were merely inconvenient, cheap options would be a nice-to-have. The adherence data says otherwise: pricing determines not just who starts but who's still on treatment at month twelve — which is where the clinical benefit actually lives. An affordable pathway isn't the budget version of care. For a large share of patients, it's the version that works, because it's the version they can keep.

Frequently Asked Questions

How many people can't afford GLP-1 medications?

KFF polling found roughly half of adults who've taken GLP-1s describe them as difficult to afford; fewer than 1 in 10 clinically eligible patients currently takes one.

Does income really affect GLP-1 outcomes?

The 2025 JAMA cohort found significantly lower discontinuation among higher-income patients. Because staying on therapy drives results, affordability functions as a clinical variable.

What's the cheapest legitimate way to get semaglutide?

For eligible Medicare beneficiaries, $50 bridge-program copays. For everyone else, compounded telehealth is the lowest tier — from $86/month at Ozari — versus $245 branded via TrumpRx. Full comparison here.

Are cheap compounded options safe?

Price doesn't determine safety — process does: licensed provider review, named pharmacies, independent certification. Our verification guide covers what to check at any price.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial results describe FDA-approved formulations in study populations and are not guarantees of individual outcomes. Always consult a licensed healthcare provider before starting, changing, or stopping any prescription medication.

Sources

• Rodriguez PJ, et al. JAMA Netw Open. 2025;8(1):e2457349
• KFF Health Tracking Poll — public opinion on GLP-1 drugs
• Ozari GLP-1 Telehealth Pricing Index